• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medical

Insmed announces results of the Phase 3 ARISE study of Arikayce for NTM lung infections caused by MAC

Insmed announced that the Phase 3 ARISE study of Arikayce amikacin liposome inhalation suspension  demonstrated the effectiveness of the QOL-B questionnaire for patient-reported outcomes. The ARISE study of Arikayce in patients with nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) was initiated in December 2020 with the … [Read more...] about Insmed announces results of the Phase 3 ARISE study of Arikayce for NTM lung infections caused by MAC

PureIMS announces planned Phase 1 trial of Levodopa Cyclops

PureIMS has announced that it intends to initiate a dose-finding study of its Levodopa Cyclops DPI titled "A pilot open-label, randomized, crossover, comparative bioavailability study of levodopa administered via Levodopa Cyclops (test product) relative to Inbrija (reference product) in healthy adult subjects" by the end of this year. In April 2023, PureIMS announced … [Read more...] about PureIMS announces planned Phase 1 trial of Levodopa Cyclops

Immune Biosolutions reports results from Phase 1 and 2 trials of IBIO123 inhaled antibody therapy for COVID-19

Immune Biosolutions has announced the publication of results from Phase 1 and 2 trials of the company's IBIO123 inhaled antibody therapy in patients with COVID-19 in The Lancet Infectious Diseases. Immune Bio announced the initiation of the Phase 1 trial in October 2021. According to the journal article, the Phase 2 study was stopped early because COVID-19 became … [Read more...] about Immune Biosolutions reports results from Phase 1 and 2 trials of IBIO123 inhaled antibody therapy for COVID-19

Galecto to discontinue development of its GB0139 DPI for the treatment of IPF after Phase 2b trial fails to meet its primary endpoint

Galecto has announced that the Phase 2b GALACTIC-1 of its GB0139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis failed to meet its primary endpoint and, as a result, the company will discontinue development of the DPI. GALACTIC-1 was initiated in February 2019. In March 2021, Galecto announced that it was discontinuing the higher dose … [Read more...] about Galecto to discontinue development of its GB0139 DPI for the treatment of IPF after Phase 2b trial fails to meet its primary endpoint

Silo Pharma says it will develop intranasal formulation of SPC-15 ketamine for the treatment of stress disorders

Silo Pharma said that it is planning to develop an intranasal formulation of its SPC-15, which includes "ketamine compositions," for the prevention and treatment of stress disorders, including anxiety and PTSD. The formulation was developed at Columbia University under a sponsored research agreement. According to Silo, US Patent no 11,622,948 ("Biomarkers for Efficacy … [Read more...] about Silo Pharma says it will develop intranasal formulation of SPC-15 ketamine for the treatment of stress disorders

Vistagen says Phase 3 PALISADE-2 trial PH94B fasedienol nasal spray for SAD met primary endpoint

Vistagen has announced that the Phase 3 PALISADE-2 public speaking challenge trial of PH94B fasedienol nasal spray in subjects with social anxiety disorder met its primary and secondary endpoints. The company announced the initiation of PALISADE-2 in September 2021 and then paused the trial in mid-2022 after PALISADE-1 failed to meet its primary endpoint. The trial … [Read more...] about Vistagen says Phase 3 PALISADE-2 trial PH94B fasedienol nasal spray for SAD met primary endpoint

Inimmune initiates Phase 1/1b trial of INI-2004 intranasal TLR4 agonist

Missoula, Montana-based Inimmune Corporation has announced the initiation of Phase 1/1b trial of its INI-2004 intranasal toll-like receptor 4 agonist, which the company is developing for the treatment of allergic rhinitis. According to the company, the Phase 1 SAD portion of the study, which is taking place in Australia, will enroll healthy volunteers and patients … [Read more...] about Inimmune initiates Phase 1/1b trial of INI-2004 intranasal TLR4 agonist

Krystal Biotech says that it will develop an inhaled formulation of its KB707 gene therapy for the treatment of solid tumors

Krystal Biotech announced that it will develop injectable and inhaled versions of its KB707 gene therapy for the treatment of malignant solid tumors, including metastatic cancer. The company said that it intends to amend an existing IND to add a clinical trial of the inhaled formulation by the end of the year, with the trial expected to begin by mid-2024. Krystal … [Read more...] about Krystal Biotech says that it will develop an inhaled formulation of its KB707 gene therapy for the treatment of solid tumors

Insilico Medicine says it intends to file IND for ISM001-055 inhalation solution for IPF

Insilico Medicine, which claims to be "a generative artificial intelligence (AI)-driven clinical-stage drug discovery company," said that it is "the first AI drug discovery company to venture into nebulized formulations" as the company plans to file an IND for its ISM001-055 inhalation solution for the treatment of idiopathic pulmonary fibrosis. According to the … [Read more...] about Insilico Medicine says it intends to file IND for ISM001-055 inhalation solution for IPF

Lupin launches Luforbec beclometasone / formoterol MDI in Germany

Lupin announced that its German subsidiary Hormosan Pharma has launched Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Germany. According to Lupin, the price of the MDI, which is a generic of Chiesi's Foster (Fostair), will be set at just over half the reference price. Luforbec has been available in the UK since 2021. Hormosan … [Read more...] about Lupin launches Luforbec beclometasone / formoterol MDI in Germany

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Interim pages omitted …
  • Page 119
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews